Comparison of Intranasal and Injectable Glucagon Administration Among Pediatric Population Responders

Yue-Pei Wang1, Francesca Bernatchez2, Sarah Chouinard-Castonguay1

  • 1CHU de Québec-Université Laval Research Centre, Centre Hospitalier de l'Université Laval, Quebec, Canada.

PubMed

Insights

Nasal glucagon is faster and easier to use than injectable glucagon for parents and school workers managing type 1 diabetes emergencies. Training with videos can improve the use of nasal glucagon in severe hypoglycemia management.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Emergency Medicine

Background:

  • Severe hypoglycemia in type 1 diabetes (T1D) requires prompt glucagon administration.
  • Ease of use and acceptability of different glucagon formulations are critical for effective emergency response.
  • Limited data exist on the comparative performance of nasal versus injectable glucagon (IG) among lay responders.

Purpose of the Study:

  • To compare the administration performance of nasal versus IG in parents of youth with T1D and school workers.
  • To evaluate enablers and barriers associated with each glucagon type and preferred learning modalities for administration training.

Main Methods:

  • 30 parents and 30 school workers underwent simulated administration of nasal and IG after watching instructional videos.
  • Performance was assessed by completion time and successful execution of critical steps.
  • Interviews explored preferred learning methods, barriers, and enablers for each glucagon type.

Main Results:

  • Nasal glucagon administration was significantly faster than IG in both groups (P < 0.001).
  • School workers had a higher success rate with nasal glucagon (90%) compared to IG (53%; P = 0.007).
  • Nasal glucagon demonstrated greater ease of use and acceptability; videos alone were sufficient for training.

Conclusions:

  • Nasal glucagon is a more practical, faster, and acceptable alternative to IG for managing severe hypoglycemia in T1D.
  • Video-based training for nasal glucagon can enhance its use by school workers, improving emergency preparedness.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
287
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
198
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
218
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176